Date: 2016-10-03
Type of information: Initiation of the trial
phase: registry study
Announcement: initiation of the trial
Company: Daiichi Sankyo (Japan)
Product:
Action mechanism:
Disease: nonvalvular atrial fibrillation in elderly patients
Therapeutic area: Cardiovascular diseases
Country: Japan
Trial details:
Latest
news: * On October 3, 2016, Daiichi Sankyo announced that it has commenced a company-initiated, large-scale registry, called ANAFIE (All Nippon AF In Elderly) Registry in Japan to study nonvalvular atrial fibrillation (NVAF) in elderly patients aged 75 years and older.
The ANAFIE Registry is the NVAF registry to date in Japan, with a planned enrollment of 30,000 elderly NVAF patients and a planned follow-up of 2 years. The objectives of the ANAFIE Registry are to 1) investigate the current status of the use of anticoagulants and their impact on outcomes, and thus identify issues that are barriers to optimal treatment in this population, and 2) identify risk factors for thrombotic and bleeding events, including intracranial hemorrhage, and thus determine the population in which direct oral anticoagulants (DOACs) could provide benefits, as well as the optimal DOAC treatment regimen, including Lixiana® (Edoxaban Tosilate Hydrate), in elderly patients with NVAF.
